Separate names with a comma.
via Bristol Myers Squibb has resumed dismissing employees as part of an ongoing workforce reduction of about 10%. A WARN notice filed in March in...
via Roche released its first-quarter 2024 earnings results on Wednesday posting a 6% decline in sales compared to the same prior year period, as...
via Biogen (BIIB.O) beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of...
via About 3.6 million overweight or obese patients with heart conditions insured under the U.S. Medicare program could be eligible for coverage of...
via Day One Biopharmaceuticals on Tuesday announced that it has secured the FDA’s accelerated approval for tovorafenib, which will be marketed...
via The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. But, thanks to blockbuster meds...
via But the first signs that H5N1 — or any new flu virus — was starting to spread from person to person would trigger a race to produce massive...
via Any new company wanting to make waves in applying artificial intelligence to drug discovery will need deep pockets and a top-tier science and...
via Degenerative vision loss significantly impacts a patient, but many find the treatment required to stabilize or improve vision — monthly...
via Demand is high for Eli Lilly’s Zepbound, and the weight-loss drug market could reach $100 billion by the end of the decade. But one thing is...
via The funds will advance an idiopathic pulmonary fibrosis medicine once owned by Eli Lilly and an antibody-drug conjugate the startup licensed...
via Neurocrine Biosciences has nabbed a phase 2 win, with its investigational med in-licensed from Takeda significantly reducing depression...
via Incyte announced Tuesday that it is buying Escient Pharmaceuticals for $750 million to gain control of a pipeline led by clinical-phase...
via Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an...
via Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that it has obtained an exclusive license from TreeFrog Therapeutics, a French-based...
via Sanofi’s rilzabrutinib has found success and met the primary endpoint in the Phase III LUNA trial in heavily pre-treated immune...
via The top 20 drugmakers — led by GLP-1 manufacturers Eli Lilly and Novo Nordisk — reported a total increase of 9.6% in market capitalization in...
via Cardinal Health (CAH.N) said on Monday its contracts with UnitedHealth Group's (UNH.N) OptumRx, one of its largest customers, will not be...
via What could become the first fast-acting drug for social anxiety is working its way through late-stage clinical trials. Everyday...
via After the FDA issued a public safety notice and sent Exactech a warning letter, the firm agreed to recall shoulder implants due to packaging...
